THE USE OF PROTEOLYTIC ENZYME INHIBITOR (TRASYLOL) IN RADIORECEPTOR ASSAY OF TSH - ITS APPLICATION TO MEASURING THYROID STIMULATING IMMUNOGLOBULINS (TSI) IN THYROID DISEASES

1978 ◽  
Vol 88 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Michizo Kishihara ◽  
Yoshinobu Nakao ◽  
Yasuto Baba ◽  
Shozo Ohgo ◽  
Shigeru Matsukura ◽  
...  
Keyword(s):  
Proteolytic Enzyme ◽  
Enzyme Inhibitor ◽  
Great Majority ◽  
Thyroid Stimulating Hormone ◽  
Radioreceptor Assay ◽  
Human Thyroid ◽  
Graves Disease ◽  
Stable Method ◽  
Thyroid Stimulating Immunoglobulins ◽  
Proteolytic Enzyme Inhibitor

ABSTRACT In order to estimate thyroid stimulating immunoglobulins (TSI) in serum, a stable, reproducible and sensitive radioreceptor assay (RRA) capable of detecting 100 μU of thyroid stimulating hormone (TSH) has been developed using a proteolytic enzyme inhibitor (Trasylol), partially purified human TSH and particulate fractions of human thyroid homogenate. The binding of 125I-labelled TSH to the crude thyroid membranes was significantly increased from 2–3 % to 15–20 % in the presence of Trasylol (2000 KIU per tube). Further investigations suggested that Trasylol might inhibit the aggregation of 125I-labelled TSH during incubation with these membranes. With this assay system, the serum immunoglobulins from a great majority of untreated patients with Graves' disease were shown to inhibit the binding of 125I-labelled TSH to those membranes more markedly than those from control subjects. Therefore, this RRA for TSH was considered to provide a sensitive and stable method for detecting TSI.

Preparation and Properties of Human Prothrombin Complex

1970 ◽  
Vol 24 (03/04) ◽  
pp. 325-333 ◽  
Author(s):  
G. H Tishkoff ◽  
L. C Williams ◽  
D. M Brown
Keyword(s):  
Molecular Weight ◽  
Proteolytic Enzyme ◽  
Enzyme Inhibitor ◽  
Specific Activity ◽  
Crystalline Form ◽  
Sedimentation Equilibrium ◽  
Crystalline Complex ◽  
Interaction Product ◽  
Proteolytic Enzyme Inhibitor ◽  
Purification Scheme

SummaryAs a corollary to our previous studies with bovine prothrombin, we have initiated a study of human prothrombin complex. This product has been isolated in crystalline form as a barium glycoprotein interaction product. Product yields were reduced compared to bovine product due to the increased solubility of the barium glycoprotein interaction product. On occasion the crystalline complex exhibited good yields. The specific activity of the crystalline complex was 1851 Iowa u/mg. Further purification of human prothrombin complex was made by removal of barium and by chromatography on Sephadex G-100 gels. The final product evidenced multiple procoagulant activities (II, VII, IX and X). The monomeric molecular weight determined by sedimentation equilibrium in a solvent of 6 M guanidine-HCl and 0.5% mercaptoethanol was 70,191 ± 3,057 and was homogeneous with respect to molecular weight. This product was characterized in regard to physical constants and chemical composition. In general, the molecular properties of human prothrombin complex are very similar to the comparable bovine product. In some preparations a reversible proteolytic enzyme inhibitor (p-aminophenylarsonic acid) was employed in the ultrafiltration step of the purification scheme to inhibit protein degradation.

scholarly journals MASSIVE THYMIC HYPERPLASIA SECONDARY TO GRAVES DISEASE

2020 ◽  
Vol 6 (3) ◽  
pp. e144-e146
Author(s):  
WingYee Wan ◽  
Jeffrey A. Colburn
Keyword(s):  
Computed Tomography ◽  
Thyroid Stimulating Hormone ◽  
Free Thyroxine ◽  
Thymic Hyperplasia ◽  
Anterior Mediastinal Mass ◽  
Graves Disease ◽  
Presenting Symptoms ◽  
Thyroid Stimulating Immunoglobulins ◽  
Computed Tomography Angiogram ◽  
Stimulating Hormone

Objective: Graves disease (GD) has a well-known association with thymic hyperplasia, which is seen histo-logically in up to 38% of patients with GD. However, there have only been approximately 100 documented cases of Graves-associated massive thymic hyperplasia. Potential mechanisms of thymic pathology are reviewed. Methods: A 24-year-old female presented to the emergency department with dyspnea, palpitations, tachycardia, anxiety, and weight loss. She was evaluated for hyperthyroidism using labs (thyroid-stimulating hormone, free thyroxine, thyroid-stimulating immunoglobulins) and imaging (radioactive iodine uptake [RAIU] scan), leading to treatment with radioiodine. A computed tomography angiogram of the chest was also performed to evaluate for pulmonary embolism given the patient's presenting symptoms. Results: Our patient was found to have undetectable thyroid-stimulating hormone, elevated free thyroxine (2.9 ng/dL), and elevated thyroid-stimulating immunoglobulins (399%). Diagnosis of GD was confirmed on RAIU scan. The computed tomography chest angiogram demonstrated a significant anterior mediastinal mass (7.9 × 6.9 × 6.3 cm). Treatment with radioiodine led to reduction of the mass by 76% in volume. Conclusion: While the patient's thyroid labs and RAIU scan were consistent with GD, the presence of massive thymic hyperplasia was atypical. However, the resolution of thymic hyperplasia after radioiodine therapy, without the use of thymectomy, was similar to other reported cases.

A comparison of porcine and human thyroid tissue in the assay of thyroid stimulating immunoglobulins

1986 ◽  
Vol 113 (3) ◽  
pp. 335-339
Author(s):  
S. de Rave ◽  
H. M.J. Goldschmidt ◽  
Y. T.J. Somers-Pijnenburg ◽  
B. Bravenboer ◽  
J. H. M. Lockefeer
Keyword(s):  
Medical Treatment ◽  
Thyroid Tissue ◽  
Human Thyroid ◽  
Graves Disease ◽  
Clinical Use ◽  
Human Thyroid Tissue ◽  
Thyroid Stimulating Immunoglobulins ◽  
Camp Generation

Abstract. The central role of Thyroid Stimulating Immunoglobulins (TSI) in the pathogenesis of the hyperthyroidism of Graves' disease has become generally accepted and a wide variety of assays for the detection of these antibodies has been developed. The dependence on the availability of human thyroid tissue makes most of these assays unsuitable for routine clinical use, a problem circumvented by the use of nonhuman thyroid tissue in some TSI assays. We therefore compared porcine and human thyroid tissue in a TSI assay based on in vitro cAMP generation. No major differences in within and between run variation were found and, with some notable exceptions, a reasonable correlation could be demonstrated between the results in both assays (R = 0.89, P < 0.001). However, the sensitivity of the porcine TSI assay is only 60% of the estimated sensitivity of the human TSI assay. In spite of the practical advantages this porcine TSI assay, and possibly also other TSI assays using non-human thyroid tissue, cannot totally replace human TSI assays. The value of these assays in predicting the outcome of medical treatment of Graves' disease remains to be established.

IMPROVEMENT OF THE SEPTIC LUNG LESION BY TREATMENT WITH A PROTEOLYTIC ENZYME INHIBITOR

1982 ◽  
Vol 57 (3) ◽  
pp. A132-A132
Author(s):  
D. L. Traber ◽  
L. Sziebert ◽  
T. Adams ◽  
N. Henriksen ◽  
L. D. Traber
Keyword(s):  
Proteolytic Enzyme ◽  
Enzyme Inhibitor ◽  
Lung Lesion ◽  
Proteolytic Enzyme Inhibitor

Effect of various drugs on the binding of thyrotrophin to thyroid plasma membranes

1982 ◽  
Vol 100 (4) ◽  
pp. 519-526
Author(s):  
Yasuto Baba ◽  
Yoshinobu Nakao ◽  
Michizo Kishihara ◽  
Nobuhisa Kobayashi ◽  
Hiroyuki Kimoto ◽  
...  
Keyword(s):  
Plasma Membranes ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Human Thyroid ◽  
Dependent Manner ◽  
Protective Effects ◽  
Proteolytic Enzyme Inhibitor ◽  
Erythrocyte Lysis ◽  
Adrenergic Blocking ◽  
Dose Dependent

Abstract. Effects of enzyme inhibitors and membraneactive drugs on the binding of 125I-labelled thyroidstimulating hormone (TSH) to human thyroid membranes and membrane adenylate cyclase (AC) activity were studied. FOY®, a synthetic polyvalent proteolytic enzyme inhibitor, Trasylol®, α- and β-adrenergic blocking agents, tranquilizers, anti-histamines and polyene antibiotics enchanced TSH binding in a dose-dependent manner, whereas selective enzyme inhibitors and adrenergic stimulating agents had no effect. Both propranolol and FOY inhibited basal and TSH stimulated AC activity of thyroid membranes. FOY, as well as propranolol was found to have protective effects on hypotonic erythrocyte lysis. These results suggest that propranolol and FOY increased TSH binding by the same mechanism, probably the so-called membrane-stabilizing effects. Although the detailed mechanisms underlying the increased TSH binding by these drugs remain unknown, they may change the membrane structure, thereby enhancing the TSH receptor affinity.

Action of a Proteolytic Enzyme Inhibitor on Blood Coagulation in Vitro

1967 ◽  
Vol 18 (01/02) ◽  
pp. 190-197 ◽  
Author(s):  
B Blombäck ◽  
Margareta Blombäck ◽  
P Olsson
Keyword(s):  
Blood Coagulation ◽  
Proteolytic Enzyme ◽  
Enzyme Inhibitor ◽  
Factor V ◽  
Generation System ◽  
Antifibrinolytic Agents ◽  
Coagulation Activity ◽  
Serum Factors ◽  
Proteolytic Enzyme Inhibitor

SummaryThe action of the kallikrein and trypsin inhibitor, Trasylol, has been studied in a three-stage thrombin generation system. It has been found that Trasylol inhibits one or several of the early reactions of blood coagulation. The inhibition of the early stages is dependent on the concentration of inhibitor, serum factors and factor VIII. The activation of factor V by tiger snake venom is not inhibited by Trasylol. The inhibition is most probably on one or several of the reactions preceding the factor V involved step.Some other known antifibrinolytic agents have also been tested for anti-coagulation activity.

A multicenter trial of the use of the proteolytic enzyme inhibitor aprotinin in colorectal surgery

1989 ◽  
Vol 32 (6) ◽  
pp. 505-508 ◽  
Author(s):  
William G. Sheridan ◽  
Ahmed A. Shandall ◽  
John Alexander-Williams ◽  
Michael R. B. Keighley ◽  
Paul B. Boulos ◽  
...  
Keyword(s):  
Colorectal Surgery ◽  
Proteolytic Enzyme ◽  
Enzyme Inhibitor ◽  
Multicenter Trial ◽  
Proteolytic Enzyme Inhibitor

Effect of a proteolytic enzyme inhibitor on the cardiopulmonary response to endotoxin

Resuscitation ◽  
1986 ◽  
Vol 14 (1-2) ◽  
pp. 91-104 ◽  
Author(s):  
D.L. Traber ◽  
T. Adams ◽  
L. Sziebert ◽  
L.D. Traber
Keyword(s):  
Proteolytic Enzyme ◽  
Enzyme Inhibitor ◽  
Proteolytic Enzyme Inhibitor
Sign in / Sign up

Export Citation Format

Share Document